The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C. · 2008

Read The CD44+/CD24- phenotype is enriched in basal-like breast tumors. by Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2481503.txt.

Introduction

Honeth and colleagues counted stem-pattern cells across 240 human breast tumors in 2008. The pattern, CD44 positive and CD24 negative, marks cells proposed to seed tumors and resist treatment. The team used double staining to locate both proteins in each tumor and matched results to tumor subtype and patient data.

The pattern appeared in 31% of tumors, anywhere from a few cells to nearly all of them. A full 35% of tumors lacked both proteins entirely. The stem pattern concentrated in basal-like tumors, the subtype lacking hormone receptors and HER2. It was near-universal in inherited BRCA1 tumors, 94% of which contained such cells. In HER2-positive tumors it was scarce, those tumors favouring the CD24-positive state instead. A gene signature built from the pattern ranked CD44 and the integrin CD49f at the top. The authors cautioned that tumor-seeding power may not live only in this cell type.

Catalog record

CREATORHoneth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE46 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2481503

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The CD44+/CD24- phenotype is enriched in basal-like breast tumors By Gabriella Honeth, Pär-Ola Bendahl, Markus Ringnér, Lao H Saal, Sofia K Gruvberger-Saal, Kristina Lövgren, Dorthe Grabau, Mårten Fernö, Åke Borg, Cecilia Hegardt Published in: Breast Cancer Research : BCR DOI: 10.1186/bcr2108 ABSTRACT Abstract Introduction Human breast tumors are heterogeneous and consist of phenotypically diverse cells. Breast cancer cells with a CD44+/CD24- phenotype have been suggested to have tumor-initiating properties with stem cell-like and invasive features, although it is unclear whether their presence within a tumor has clinical implications. There is also a large heterogeneity between tumors, illustrated by reproducible stratification into various subtypes based on gene expression profiles or histopathological features. We have explored the prevalence of cells with different CD44/CD24 phenotypes within breast cancer subtypes. Methods Double-staining immunohistochemistry was used to quantify CD44 and CD24 expression in 240 human breast tumors for which information on other tumor markers and clinical characteristics was available. Gene expression data were also accessible for a cohort of the material. Results A considerable heterogeneity in CD44 and CD24 expression was seen both between and within tumors. A complete lack of both proteins was evident in 35% of the tumors, while 13% contained cells of more than one of the CD44+/CD24-, CD44-/CD24+ and CD44+/CD24+ phenotypes. CD44+/CD24- cells were detected in 31% of the tumors, ranging in proportion from only a few to close to 100% of tumor cells. The CD44+/CD24- phenotype was most common in the basal-like subgroup – characterized as negative for the estrogen and progesterone receptors as well as for HER2, and as positive for cytokeratin 5/14 and/or epidermal growth factor receptor, and particularly common in BRCA1 hereditary tumors, of which 94% contained CD44+/CD24- cells. The CD44+/CD24- phenotype was surprisingly scarce in HER2+ tumors, which had a predominantly CD24+ status. A CD44+/CD24- gene expression signature was generated, which included CD44 and α6-integrin (CD49f) among the top-ranked overexpressed genes. Conclusion We demonstrate an association between basal-like and particularly BRCA1 hereditary breast cancer and the presence of CD44+/CD24- cells. Not all basal-like tumors and very few HER2+ tumors, however, contain CD44+/CD24- cells, emphasizing that a putative tumorigenic ability may not be confined to cells of this phenotype and that other breast cancer stem cell markers remain to be identified. INTRODUCTION Human breast cancer is a truly complex disease with a large inter-tumoral and intra-tumoral heterogeneity resulting in highly variable clinical behavior and response to therapy. The maintenance of the heterogeneity of cells within a tumor is not fully understood. Possibly, every cell within a tumor may have a capacity to proliferate and form new tumors, although the likelihood for each cell is very low. Alternatively, only a small subset of cells with distinct characteristics has the capacity to maintain tumor growth. A population of CD44+/CD24-/low cells has been demonstrated to have tumor-initiating properties in breast cancer [1]. This tumorigenic phenotype has been associated with stem cell-like characteristics [2], with enhanced invasive properties [3], with radiation resistance [4] and with distinct genetic profiles suggesting correlation to adverse prognosis [5]. The prevalence of CD44+/CD24-/low cells within breast tumors, however, has not been significantly associated with clinical characteristics – although tumors with a higher fraction of CD44+/CD24- cells were more commonly found in patients diagnosed with distant metastases [6]. Breast cancers have been classified based on their gene expression profiles into luminal A and B, basal-like, HER2+ and normal breast-like subtypes [7-10]. These subtypes have been associated with diverse tumor characteristics and clinical outcome. The luminal subtypes are associated with expression of the estrogen receptor (ER), while basal-like and normal-like tumors are essentially all ER-negative, as are the majority of HER2+ tumors. Multiple studies have demonstrated basal-like tumors to have a particularly poor prognosis [8,9,11], although it is unclear whether basal-like tumors have a significantly worse clinical outcome than other ER-negative tumors [12]. Immunohistochemical features have been used to characterize basal-like tumors as typically negative for ER, for the progesterone receptor (PgR) and for HER2 but positive for basal cytokeratins (CK5/6/14/17), for epidermal growth factor receptor (EGFR) and/or for c-kit [13-15]. A correlation of the CD44+/CD24-/low phenotype to specific breast cancer subtypes has not yet been reported in human breast tumors. In the present article we have determined the expression of CD44 and CD24 in human breast tumors using double-staining immunohistochemistry and have correlated the presence of CD44+/CD24- cells to subgroups of breast cancer, classified using the expression of ER, PgR, HER2, CK5/14 and EGFR, as well as by mRNA expression profiles. We demonstrate an association of the CD44+/CD24- phenotype to basal-like and BRCA1 hereditary breast cancer. MATERIALS AND METHODS Patients We studied 240 tumors from a cohort of 445 patients surgically treated for stage II breast cancer (age 31 to 81 years), diagnosed in the South Swedish Health Care Region between 1985 and 1994 and originally participating in two randomized clinical trials [16,17]. All patients received 2 years of adjuvant tamoxifen treatment, without stratification according to ER status. The median follow-up time for patients alive and free from metastasis at the last follow-up visit was 5.3 years. The current study was approved by the Lund University Medical Ethics Committee. Tumor characteristics Fresh-frozen tumor tissue was used for routine determination of cytosolic ER and PgR, as well as the S-phase fraction, using an enzyme immunoassay and DNA flow cytometry, respectively, as described earlier [18,19]. Cores of 0.6 mm diameter formalin-fixed, paraffin-embedded tumor tissue were used to generate tissue microarrays (TMAs) for the 445 cases. Three cores from every individual tumor were arrayed. These TMAs have been used for immunohistochemical staining of CK5, CK14, EGFR and cytokeratin clone AE1/AE3 as described previously [12,20]. A pathologist re-evaluated the histological type on whole formalin-fixed paraffin-embedded sections [21]. BRCA1 tissue microarray An additional TMA consisting of tumors from 23 BRCA1 germline mutation carriers, diagnosed in Sweden between 1980 and 2001, was used for evaluation purpose. This TMA was generated as described above, including two or three cores from each tumor. Immunohistochemical staining Sections (4 μm) of the TMA blocks were mounted on Dako REAL™ Capillary Gap Microscope Slides (DAKO, Glostrup, Denmark), were deparaffinized in xylene and were rehydrated in ethanol. Antigen retrieval was achieved either by placing slides in Tris-ethylenediamine tetraacetic acid buffer (pH 9.0) at 125°C in a 2100 Retriever (PickCell Laboratories, Amsterdam, the Netherlands) for 5 minutes (CD44/CD24), or by microwaving the slides in Tris-ethylenediamine tetraacetic acid buffer (pH 9.0) for 7 minutes at 800 W followed by 15 minutes at 350 W (HER2). Double-immunostaining with antibodies for detection of CD44 and CD24 was performed by an Autostainer (DAKO) using EnVision G|2 Doublestain System Rabbit/Mouse (DAB+/Permanent Red) (DAKO) according to the manufacturer's instructions. Antibodies for the detection of CD44 (Clone 156-3C11, 1:800) and CD24 (Clone SN3b, 1:400) were purchased from Neomarkers (Fremont, CA, USA). CD44 was detected with Permanent Red and CD24 was detected using diaminobenzidene (DAB). HER2 was detected with a rabbit polyclonal primary antibody (A0485, 1:1,000; DAKO) followed by EnVision™ on a TechMate™ (DAKO). All slides were counterstained with hematoxylin for the identification of nuclei. Immunohistochemical evaluation The scoring was performed twice by one person in a blinded fashion. All unclear cases were discussed with a pathologist. In case of discrepant staining between the three cores from the

Read the complete text